<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Intracoronary stent restenosis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Intracoronary stent restenosis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Intracoronary stent restenosis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Thomas Levin, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Donald Cutlip, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Stephan Windecker, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Todd F Dardas, MD, MS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Mar 15, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although intracoronary stent restenosis (ISR) is much less common with the use of drug-eluting stents (DES) than with bare-metal stents (BMS), the number of stents being implanted in interventional practice and the ongoing risk for restenosis over time means that the treatment of ISR remains an important clinical challenge. In a report from the National Cardiovascular Data Registry in 2020, percutaneous coronary intervention (PCI) for ISR represented 10.6 percent of all PCI procedures [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1558346535">
         <span class="h1">
          DEFINITIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         After a successful procedure, coronary stents can fail to maintain vessel patency due to either restenosis or stent thrombosis. Restenosis is a gradual re-narrowing of the stented segment that occurs mostly between 3 to 12 months after stent placement. It usually presents as recurrent angina, but can present as acute myocardial infarction in approximately 10 percent of patients. It can usually be managed by repeat percutaneous revascularization.
        </p>
        <p>
         In contrast, stent thrombosis is an abrupt thrombotic occlusion of a previously widely patent stent. It is a catastrophic complication that presents as sudden death or large myocardial infarction in most patients. Despite successful repeat revascularization, the six-month mortality is high. (See
         <a class="medical medical_review" href="/z/d/html/87310.html" rel="external">
          "Coronary artery stent thrombosis: Clinical presentation and management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1582.html" rel="external">
          "Coronary artery stent thrombosis: Incidence and risk factors"
         </a>
         .)
        </p>
        <p>
         In this topic, intracoronary stent restenosis (ISR) and in-stent restenosis refer to the same issue.
        </p>
        <p>
         The following are widely agreed upon definitions related to ISR  (
         <a class="graphic graphic_table graphicRef56696" href="/z/d/graphic/56696.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid2">
          2
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Restenosis
         </strong>
         – A reduction in lumen diameter after percutaneous coronary intervention due to arterial damage and subsequent neointimal tissue proliferation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Binary angiographic restenosis
         </strong>
         – A ≥50 percent luminal narrowing at follow-up angiography.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical restenosis
         </strong>
         – The presence of both binary angiographic restenosis and clinical symptoms or signs of ischemia (either at rest or with stress)
         <strong>
          OR
         </strong>
         restenosis with a ≥70 percent reduction in lumen diameter even in the absence of clinical symptoms or signs.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          INCIDENCE OF RESTENOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The incidence of restenosis depends on the definition of restenosis (see
         <a class="local">
          'Definitions'
         </a>
         above), type of stent, and the complexity of the lesion(s) stented. Restenosis rates are considerably higher in more complex lesion subsets, such as small vessels, long lesions, and bifurcations. (See
         <a class="medical medical_review" href="/z/d/html/1571.html" rel="external">
          "Percutaneous coronary intervention of specific coronary lesions"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bare metal stents
         </strong>
         – With decreasing use of bare metal stents (BMS) in favor of newer drug-eluting stents (DES), data for BMS restenosis are mostly from older studies, although the lessons learned regarding restenosis outcomes remain of interest. A pooled analysis of 6186 patients from six major clinical trials assessed frequency and predictors of restenosis among BMS. The frequency of clinical restenosis was defined as target lesion or target vessel revascularization (TVR) beyond 30 days, death, or myocardial infarction in the target vessel territory [
         <a href="#rid3">
          3
         </a>
         ]. At one year, target lesion revascularization (TLR) was performed in 12 percent and TVR in 14.1 percent. These values were more than two-thirds higher than those at six months (6.9 and 8 percent). Clinically relevant restenosis occurred in only about one-half of patients with angiographic restenosis (defined as ≥50 percent diameter stenosis). This was mostly a matter of degree, since 50 to 70 percent angiographic stenosis is unlikely to cause symptoms. The incidence of TLR was much higher with more than 70 percent diameter stenosis (73 versus 26 percent for less than 60 percent diameter stenosis).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Clinical restenosis with BMS is a relatively early event, most often becoming clinically evident within the first 6 to 12 months after the procedure [
         <a href="#rid4">
          4
         </a>
         ]. After one year, recurrent ischemia is more likely to be due to new or progressive disease at another site rather than restenosis. The magnitude of this difference was illustrated in a review of 1228 patients who were followed for five years [
         <a href="#rid4">
          4
         </a>
         ]. After the first year, the annual hazard rate was 1.7 percent for target lesion events compared with 6.3 percent for nontarget lesion events.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Drug-eluting stents
         </strong>
         – The rate of intracoronary stent restenosis (ISR) has been reported between 3 to 20 percent, depending on which DES is evaluated, the duration of follow-up, and the complexity of the lesions in which the stents were placed [
         <a href="#rid2">
          2
         </a>
         ]. The following three studies provide representative outcomes:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For first-generation DES (
         <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">
          sirolimus
         </a>
         or
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          paclitaxel
         </a>
         DES), the rate of restenosis is between 13 and 16 percent at five years [
         <a href="#rid5">
          5,6
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1575.html" rel="external">
          "Intracoronary stents: Stent types", section on 'Early-generation drug-eluting stents'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         In a 2020 meta-analysis of 19 trials in 25,032 patients who underwent PCI, very late stent-related events occurred between one and five years after PCI at a rate of approximately 2 percent per year; this was true for all stent types [
         <a href="#rid7">
          7
         </a>
         ]. Target vessel revascularization occurred in 6.9 percent of participants at five years. In a prior pooled analysis of multiple studies comparing everolimus-eluting with zotarolimus-eluting stents, the rates of TVR at up to five years of follow-up were 6.3 and 5 percent, respectively [
         <a href="#rid8">
          8
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1575.html" rel="external">
          "Intracoronary stents: Stent types", section on 'Zotarolimus-eluting stents'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Multiple trials have demonstrated that both first-generation
         <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">
          sirolimus
         </a>
         and
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          paclitaxel
         </a>
         DES and second-generation
         <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">
          everolimus
         </a>
         and zotarolimus DES markedly reduced the incidence of ISR and the rate of TLR by about 75 percent compared with BMS. The data supporting this conclusion are discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/1575.html" rel="external">
          "Intracoronary stents: Stent types"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Reduction in lumen diameter following stent implantation is the result of arterial damage with subsequent neointimal tissue proliferation. Typically, neointimal proliferation is distributed uniformly along the length of the stent [
         <a href="#rid9">
          9-11
         </a>
         ], but may also be relatively focal. The neointimal proliferation occurs in association with macrophage accumulation and extensive neovascularization, suggesting a role for organization of mural thrombus [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
         Consistent with this hypothesis are the pathologic findings in 55 stents in 35 coronary arteries from patients who died, had repeat coronary artery bypass graft (CABG) surgery, or underwent transplantation. The mean duration of stent placement was 39 days [
         <a href="#rid13">
          13
         </a>
         ]. The following abnormalities were noted:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fibrin, platelets, and neutrophils, indicating thrombus formation and acute inflammation, have been demonstrated at stent struts evaluated ≤11 days after placement. Inflammation was more pronounced in struts that were embedded in a lipid core and those in contact with damaged media.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stents evaluated at a later time showed neointimal growth that increased as the ratio of stent area to reference lumen area increased. Neointimal thickness was greater for struts associated with medial damage than for those in contact with plaque. Over time, extracellular matrix accumulation may play a greater role than cell proliferation in neointimal thickening [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Although there is an increase in neointimal tissue with subsequent reduction in the minimal luminal diameter during the first six months after stent placement, there may be no further reduction in luminal diameter or even regression at one year and a further increase in diameter at later time points [
         <a href="#rid15">
          15-17
         </a>
         ]. Serial angiography and angioscopy found the following sequence of changes [
         <a href="#rid16">
          16
         </a>
         ]. There was initial thickening of the neointima that became nontransparent at six months. Thereafter, the neointima became thin and transparent (ie, the majority of the stent was visible). This correlated with an increase in the luminal diameter.
        </p>
        <p class="headingAnchor" id="H1558346569">
         <span class="h2">
          Mechanisms
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mechanisms to explain the observations of inflammation, mural thrombus, and neointimal tissue growth include [
         <a href="#rid2">
          2
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Biologic factors, such as resistance to the drug component of stents
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypersensitivity
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mechanical factors such as stent underexpansion or stent fracture
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Technical factors such as barotrauma outside the stented segment
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Neoatherosclerosis has been increasingly recognized as an important factor in DES restenosis, especially in late restenosis (beyond one year) [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Patterns of restenosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patterns of intracoronary stent restenosis (ISR) have been described as focal or diffuse. However, in order to further classify the types of restenosis, an angiographic classification was developed in a study of 288 ISR lesions in 245 patients who had received BMS [
         <a href="#rid19">
          19
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pattern I describes a focal (&lt;10 mm in length) lesion and was found in 42 percent of patients. Subsequent target lesion revascularization (TLR) was performed in 19 percent of patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pattern II describes ISR &gt;10 mm within the stent and was present in 21 percent of patients; 35 percent required TLR.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pattern III describes ISR &gt;10 mm extending outside the stent; TLR performed in 50 percent of patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pattern IV describes a totally occluded stent, which was found in 7 percent of patients; 83 percent underwent TLR.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          PREDICTORS IN BMS
         </span>
         <span class="headingEndMark">
          —
         </span>
         In a review of 1084 patients who underwent follow-up angiography six months after bare metal stent (BMS) placement, the incidence of restenosis is related to the number of risk factors present (as low as 16 percent in the absence of any risk factors [diabetes, multiple stents, and minimal luminal diameter after stenting &lt;3 mm]) [
         <a href="#rid20">
          20
         </a>
         ], and as high as 59 percent when at least three factors were present  (
         <a class="graphic graphic_figure graphicRef78635" href="/z/d/graphic/78635.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Angiographic factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         A number of angiographic risk factors have been identified for stent restenosis, mostly with BMS [
         <a href="#rid3">
          3,21-30
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1571.html" rel="external">
          "Percutaneous coronary intervention of specific coronary lesions"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Restenotic target lesion [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Longer stented stenosis length and stent length [
         <a href="#rid3">
          3,24,31,32
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Smaller vessel size.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ostial lesion location.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Preinterventional lesion site plaque burden (plaque/total arterial area) and amount of residual plaque burden after stent implantation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Longitudinal straightening effect and post-stent changes in vessel angulation ≥9.1 degrees [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Minimal lumen diameter &lt;3 mm at the end of the procedure [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Minimum stent area and in-stent diameter [
         <a href="#rid3">
          3,32
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Late lumen loss, which is due to in-stent neointimal hyperplasia, is defined as the difference between the minimum lumen diameter immediately after stenting and the minimum lumen diameter at six- to eight-month angiographic follow-up. It is an important predictor of the risk of clinical restenosis with both BMS and drug-eluting stents (DES) and appears to be more reliable than binary angiographic restenosis (&gt;50 percent diameter stenosis at follow-up) [
         <a href="#rid33">
          33-35
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The morphology of the coronary lesion also may have predictive value  (
         <a class="graphic graphic_table graphicRef80401" href="/z/d/graphic/80401.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid36">
          36,37
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Type A lesions – High success and low restenosis rate.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Type B lesions – Intermediate success and moderate risk of restenosis; this has been further modified to type B1 (one adverse type B characteristic) and type B2 (more than one type B characteristic).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Type C lesions – Low success and high risk of restenosis.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Clinical factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Studies of BMS identified a number of independent clinical predictors of stent restenosis and the need for target vessel revascularization (TVR), including female sex, diabetes, hypertension, weight and body mass index, multivessel disease, and the use of multiple stents [
         <a href="#rid3">
          3,21-23,30
         </a>
         ].
        </p>
        <p>
         Cigarette smokers require target lesion revascularization (TLR) significantly less frequently than nonsmokers (6.6 versus 10.1 percent in one study) [
         <a href="#rid38">
          38,39
         </a>
         ]. Despite this difference in clinical restenosis, the angiographic restenosis rate does not differ between the groups [
         <a href="#rid38">
          38,40
         </a>
         ], and the rates of subsequent death and myocardial infarction are significantly higher for smokers [
         <a href="#rid39">
          39
         </a>
         ]. Explanations for this paradox include a reduced sensitivity to restenosis or a greater reluctance to seek medical attention for recurrent angina in smokers [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p>
         A contact allergy to metal compounds, particularly nickel, released from stainless steel stents may contribute to the development of stent restenosis, although the evidence for this is limited. Studies evaluating the association between metal allergy and stent restenosis are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/5556.html" rel="external">
          "Nickel hypersensitivity and coronary artery stents"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Strut thickness
         </span>
         <span class="headingEndMark">
          —
         </span>
         Strut thickness may influence the development of stent restenosis [
         <a href="#rid41">
          41-43
         </a>
         ]. This was evaluated in the ISAR-STEREO trial in which 651 patients with lesions in vessels &gt;2.8 mm in diameter were randomly assigned to a BMS with a thin (50 micrometers) or thick (140 micrometers) strut [
         <a href="#rid41">
          41
         </a>
         ]. At six months, the thin strut group had a significantly lower incidence of angiographic restenosis (15 versus 26 percent for the thick strut, relative risk [RR] 0.58) and a lesser likelihood of reintervention for clinical restenosis (8.6 versus 13.8 percent, RR 0.62).
        </p>
        <p>
         The companion ISAR-STEREO-2 trial compared the same stent geometry, fabricated with either thin or thick (140 micrometers) struts in 611 patients [
         <a href="#rid42">
          42
         </a>
         ]. Procedural success was ≥99 percent in both groups, but device success was lower with the thin stent (87 versus 99 percent with the thick stent). The thin stent was associated with significant reductions in angiographic restenosis at six months (18 versus 31 percent) and TVR at one year (12 versus 22 percent). There was no difference in the combined endpoint of death or MI at one year.
        </p>
        <p>
         Continued improvement in stent engineering, including thinner struts, has been associated with improved safety and effectiveness.
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Mechanical problems
         </span>
         <span class="headingEndMark">
          —
         </span>
         Technical problems associated with stent deployment contribute to restenosis in a significant number of patients. In a review of 1090 patients with restenosis in BMS who underwent intravascular ultrasound (IVUS), mechanical complications were considered to contribute in 4.5 percent, while an additional 20 percent had stent underexpansion as a contributing factor [
         <a href="#rid44">
          44
         </a>
         ]. These findings highlight the need for optimal stenting, as with the use of high pressure balloon dilation with or without IVUS. (See
         <a class="medical medical_review" href="/z/d/html/1569.html" rel="external">
          "Percutaneous coronary intervention with intracoronary stents: Overview"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h2">
          Stenting of multiple lesions
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients who undergo stent placement in multiple lesions, the restenosis rate appears to be higher for a lesion when a companion lesion develops restenosis. One study evaluated 1244 patients who underwent stent placement in 1734 lesions. The restenosis rate for single, double, or ≥3 lesion stenting was 24, 29, and 34 percent, respectively, on a per lesion basis and 24, 44, and 63 percent, respectively, on a per patient basis [
         <a href="#rid45">
          45
         </a>
         ]. The risk of a lesion developing restenosis was 2.5 times higher if a companion lesion had restenosis, an effect that was independent of all other clinical factors associated with restenosis. (See
         <a class="medical medical_review" href="/z/d/html/1571.html" rel="external">
          "Percutaneous coronary intervention of specific coronary lesions", section on 'Multivessel revascularization'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H84738363">
         <span class="h1">
          PREDICTORS IN DES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although restenosis is significantly less common with drug-eluting stents (DES) than bare metal stents (BMS), it still occurs at a rate between 3 and 20 percent depending on the duration of follow-up and the complexity of the initial lesion. (See
         <a class="local">
          'Incidence of restenosis'
         </a>
         above.)
        </p>
        <p>
         Predictors of target lesion revascularization (TLR) (an approximation of restenosis) in patients receiving
         <strong>
          zotarolimus- or everolimus-eluting stents
         </strong>
         were evaluated in the RESOLUTE All-Comers trial [
         <a href="#rid46">
          46
         </a>
         ]. At four years, major predictors of TLR, which occurred in 8.6 percent of patients, included insulin-treated diabetes (odds ratio [OR] 1.97), treatment of saphenous vein grafts (OR 2.28), ostial lesions (OR 2.17), or intracoronary stent restenosis (ISR) (OR 2.24). (See
         <a class="medical medical_review" href="/z/d/html/1575.html" rel="external">
          "Intracoronary stents: Stent types", section on 'Everolimus- versus zotarolimus-eluting stents'
         </a>
         .)
        </p>
        <p>
         In an angiographic follow-up study of 238 patients who underwent
         <strong>
          sirolimus-eluting stent
         </strong>
         placement in complex lesions, the following characteristics were identified as independent multivariate predictors of angiographic restenosis: treatment of ISR (OR 4.16); ostial location (OR 4.84); diabetes (OR 2.63); total stented length (per 10 mm increase, OR 1.42); reference diameter (per 1 mm increase, OR 0.46); and left anterior descending artery (OR 0.30) [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p>
         In another angiographic follow-up study of 1845 patients who underwent implantation of either
         <strong>
          sirolimus-eluting stents
         </strong>
         <strong>
          or paclitaxel-eluting stents
         </strong>
         , the following were found to be independent multivariate predictors of angiographic restenosis: vessel size (per 0.5 mm decrease, OR 1.74, 95% CI 1.31-2.32); final diameter stenosis (per 5 percent increase, OR 1.30, 95% CI 1.15-1.47); and sirolimus-eluting stents compared with paclitaxel-eluting stent (0.60, 95% CI 0.44-0.81) [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h1">
          CLINICAL PRESENTATION AND DIAGNOSIS OF ISR
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with prior placement of an intracoronary stent, recurrent symptoms of myocardial ischemia, usually in a stable pattern, may be due to restenosis, incomplete revascularization at the time of the initial stent placement, or disease progression elsewhere. The diagnosis of intracoronary stent restenosis (ISR) is confirmed by coronary angiography, usually performed as a prelude to repeat catheter-based therapy in the same sitting. (See
         <a class="medical medical_review" href="/z/d/html/1472.html" rel="external">
          "Approach to the patient with suspected angina pectoris", section on 'History'
         </a>
         .)
        </p>
        <p>
         An appreciable proportion of patients with bare metal stents (BMS) can present with an acute coronary syndrome (3 to 20 percent) [
         <a href="#rid48">
          48-50
         </a>
         ]. A similarly high frequency of acute coronary syndrome (mostly unstable angina) has been noted with restenosis in drug-eluting stents (DES). In two small reports of patients with DES restenosis, 27 and 50 percent presented with a diagnosis of unstable angina pectoris and 5 and 11 percent presented with myocardial infarction [
         <a href="#rid1">
          1,51,52
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1582.html" rel="external">
          "Coronary artery stent thrombosis: Incidence and risk factors"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h1">
          MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The indications for coronary angiography and repeat revascularization in patients with prior stenting and stable angina are similar to those for patients without prior intervention. (See
         <a class="medical medical_review" href="/z/d/html/1557.html" rel="external">
          "Chronic coronary syndrome: Indications for revascularization", section on 'Indications'
         </a>
         .)
        </p>
        <p>
         Most patients who are diagnosed with intracoronary stent restenosis(ISR) and who undergo revascularization will undergo repeat stenting. Revascularization with coronary artery bypass graft (CABG) surgery should be considered in patients who are deemed to not be candidates for percutaneous intervention or who meet the established criteria for its use in patients with stable angina; this may include patients with recurrent, diffuse, or occlusive ISR involving a substantial myocardial territory. Patient preference plays an important role in decision-making at the time of symptomatic ISR. The relative benefits and risks of medical, percutaneous, and surgical treatments need to be discussed. In particular, the need for long-term dual antiplatelet therapy (
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         and platelet P2Y
         <sub>
          12
         </sub>
         receptor blocker) with DES must be understood by the patient. (See
         <a class="medical medical_review" href="/z/d/html/1579.html" rel="external">
          "Revascularization in patients with stable coronary artery disease: Coronary artery bypass graft surgery versus percutaneous coronary intervention", section on 'Multivessel disease'
         </a>
         .)
        </p>
        <p>
         We place a newer generation DES within the original stent in most cases. Percutaneous coronary intervention using other techniques such as plain old balloon angioplasty placement of a BMS, or intracoronary radiation, is performed less often. The use of drug-eluting balloon (DEB) angioplasty, rather than placement of a newer generation DES may be reasonable in those locations where the device is available.
        </p>
        <p>
         Specialized revascularization devices, such as rotational or directional atherectomy and laser angioplasty are used infrequently to treat ISR. These tools are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1567.html" rel="external">
          "Specialized revascularization devices in the management of coronary heart disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1565.html" rel="external">
          "Coronary artery bypass graft surgery: Prevention and management of vein graft stenosis", section on 'Atherectomy'
         </a>
         .)
        </p>
        <p>
         Our recommendations for antiplatelet therapy after ISR are similar to the broad population of patients who receive intracoronary stents. (See
         <a class="medical medical_review" href="/z/d/html/1572.html" rel="external">
          "Long-term antiplatelet therapy after coronary artery stenting in stable patients", section on 'Summary and recommendations'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H555826765">
         <span class="h2">
          Role of imaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         We perform intravascular ultrasound or OCT imaging of the ISR region in all patients. These imaging techniques allow for identification of the most likely mechanism of restenosis, such as stent underexpansion of the original stent, and help guide management. For example, if underexpansion is found, high-pressure balloon dilation may be preferred rather than additional stenting. (See
         <a class="medical medical_review" href="/z/d/html/16536.html" rel="external">
          "Intravascular ultrasound, optical coherence tomography, and angioscopy of coronary circulation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H555826772">
         <span class="h2">
          Choice of device
         </span>
         <span class="headingEndMark">
          —
         </span>
         Placement of a newer generation drug-eluting stent (DES), and in particular an everolimus-eluting stent, is the preferred treatment for patients with ISR, irrespective of whether the original stent was bare metal or drug-eluting. The various potential percutaneous coronary interventional (PCI) techniques of plain old balloon angioplasty, bare metal stenting, or older generation stenting, newer generation stenting  (
         <a class="graphic graphic_table graphicRef65603" href="/z/d/graphic/65603.html" rel="external">
          table 3
         </a>
         ), atherectomy, brachytherapy, and DEBs, have been compared in multiple studies [
         <a href="#rid25">
          25,53-71
         </a>
         ].
        </p>
        <p>
         These studies have established the superiority of newer generation DES to all other PCI devices. A 2015 well-performed network meta-analysis evaluated 27 trials (n = 5923) which compared everolimus-eluting stent with one or more of the other devices and noted the following [
         <a href="#rid72">
          72
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The primary end point of percent diameter stenosis at angiographic follow-up occurred less often with everolimus-eluting stents: -9 percent (95% CI -15.8 to -2.2) compared with drug-coated balloon; -9.4 percent (95% CI -17.4 to -1.4 percent) compared with sirolimus-eluting stents; -10.2 percent (95% CI -18.4 to -2 percent) compared with paclitaxel-eluting stents; -19.2 (95% CI -28.2 to -10.4 percent) compared with vascular brachytherapy; -23.4 percent (95% CI –36.2 to -10.8 percent) compared with BMS; -24. 2 percent (95% CI -32.2 to -16.4 percent) compared with balloon angioplasty; and -31.8 percent (95% CI -44.8 to -18.6 percent) compared with a rotablator.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         PCI with everolimus-eluting stents was associated with a lower risk of target lesion revascularization (TLR) than all other strategies.
        </p>
        <p>
        </p>
        <p>
         A 2015 meta-analysis evaluated patients at one year or shorter [
         <a href="#rid72">
          72
         </a>
         ]. Three-year follow-up of the RIBS IV study (included in the 2015 meta-analysis), which compared EES with DEB, found that the combined clinical outcome of cardiac death, myocardial infarction, and target lesion revascularization was lower with EES (12.3 versus 20.1 percent; hazard ratio 0.57, 95% CI 0.34-0.96) [
         <a href="#rid73">
          73
         </a>
         ].
        </p>
        <p>
         Despite the apparent superiority of the everolimus-eluting stents compared with a DEB, we believe it has some role, particularly as the network meta-analysis discussed above suggests, that it may be superior to other devices. For example, patients who are not good candidates for long-term dual antiplatelet therapy, those in whom there is a concern about having too much metal (eg, three concentric stents) in one location, and when compromise of flow in a side branch is a concern may be reasonable candidates for a DEB. These devices are not approved in the United States. Assessing their role in the setting of intermediate effectiveness, as suggested in the meta-analysis above, and associated benefit of avoiding additional stenting will require thoughtful trial designs.
        </p>
        <p>
         Occasionally, we use a scoring (cutting) balloon prior to stenting to increase the likelihood of achieving an optimal final internal luminal diameter. (See
         <a class="medical medical_review" href="/z/d/html/1567.html" rel="external">
          "Specialized revascularization devices in the management of coronary heart disease", section on 'Cutting balloon angioplasty'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H356813861">
         <span class="h1">
          RECOMMENDATIONS OF OTHERS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The 2014 European Society of Cardiology/European Association for Cardio-Thoracic Surgery guideline on myocardial revascularization recommends either drug-eluting stent (DES) or drug-coated balloons for the treatment of intracoronary stent restenosis (ISR) (bare metal stents [BMS] or DES) and consideration of CABG for recurrent episodes of diffuse ISR [
         <a href="#rid74">
          74
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1307443440">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/119297.html" rel="external">
          "Society guideline links: Percutaneous coronary intervention"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H30">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/3444.html" rel="external">
          "Patient education: Angina treatment — medical versus interventional therapy (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/3434.html" rel="external">
          "Patient education: Stenting for the heart (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H31">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Introduction
         </strong>
         – Restenosis is a gradual re-narrowing of the stented segment that occurs mostly between 3 and 12 months after stent placement. It usually presents as recurrent angina, but it can also present as acute myocardial infarction in approximately 10 percent of patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Revascularization
         </strong>
         –
         <strong>
         </strong>
         We perform coronary artery revascularization in most patients diagnosed with clinically significant intracoronary stent restenosis (ISR) rather than a continuation of medical therapy in an attempt to control symptoms. Indications for repeat revascularization in patients with ISR are similar compared with patients without prior stent placement.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We perform percutaneous coronary intervention in most patients with ISR rather than coronary artery bypass grafting (CABG). (See
         <a class="local">
          'Management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Intracoronary imaging
         </strong>
         – Prior to percutaneous coronary intervention for restenosis, we perform intracoronary imaging in most cases to determine if the original stent is adequately expanded, to assess for other restenosis mechanisms, and to further evaluate the size of the reference vessel. (See
         <a class="local">
          'Role of imaging'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Long-term antiplatelet therapy
         </strong>
         – Our recommendations for antiplatelet therapy are similar to the broad population of patients who receive intracoronary stents. (See
         <a class="medical medical_review" href="/z/d/html/1572.html" rel="external">
          "Long-term antiplatelet therapy after coronary artery stenting in stable patients", section on 'Summary and recommendations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Type of stent
         </strong>
         – In patients with ISR (bare metal stents [BMS] or drug-eluting stents [DES]) who require repeat revascularization, we recommend stenting using a current generation DES, and in particular, an everolimus-eluting stent, rather than treating with a BMS, balloon angioplasty, and intracoronary radiation (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ) [
         <a href="#rid75">
          75
         </a>
         ]. The use of a drug-eluting balloon is also a reasonable option where available. (See
         <a class="local">
          'Management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Patients unlikely to adhere with long-term DAPT
         </strong>
         – In patients who are unlikely to adhere to a recommendation for long-term dual antiplatelet therapy, alternatives include continuation of medical therapy, balloon angioplasty or repeat BMS, or CABG surgery. (See
         <a class="local">
          'Management'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Moussa ID, Mohananey D, Saucedo J, et al. Trends and Outcomes of Restenosis After Coronary Stent Implantation in the United States. J Am Coll Cardiol 2020; 76:1521.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dangas GD, Claessen BE, Caixeta A, et al. In-stent restenosis in the drug-eluting stent era. J Am Coll Cardiol 2010; 56:1897.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cutlip DE, Chauhan MS, Baim DS, et al. Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. J Am Coll Cardiol 2002; 40:2082.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cutlip DE, Chhabra AG, Baim DS, et al. Beyond restenosis: five-year clinical outcomes from second-generation coronary stent trials. Circulation 2004; 110:1226.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kimura T, Morimoto T, Nakagawa Y, et al. Very late stent thrombosis and late target lesion revascularization after sirolimus-eluting stent implantation: five-year outcome of the j-Cypher Registry. Circulation 2012; 125:584.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Räber L, Wohlwend L, Wigger M, et al. Five-year clinical and angiographic outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stents: results of the Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization LATE trial. Circulation 2011; 123:2819.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Madhavan MV, Kirtane AJ, Redfors B, et al. Stent-Related Adverse Events &gt;1 Year After Percutaneous Coronary Intervention. J Am Coll Cardiol 2020; 75:590.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piccolo R, Stefanini GG, Franzone A, et al. Safety and efficacy of resolute zotarolimus-eluting stents compared with everolimus-eluting stents: a meta-analysis. Circ Cardiovasc Interv 2015; 8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoffmann R, Mintz GS, Dussaillant GR, et al. Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation 1996; 94:1247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kearney M, Pieczek A, Haley L, et al. Histopathology of in-stent restenosis in patients with peripheral artery disease. Circulation 1997; 95:1998.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kornowski R, Hong MK, Tio FO, et al. In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol 1998; 31:224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Komatsu R, Ueda M, Naruko T, et al. Neointimal tissue response at sites of coronary stenting in humans: macroscopic, histological, and immunohistochemical analyses. Circulation 1998; 98:224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farb A, Sangiorgi G, Carter AJ, et al. Pathology of acute and chronic coronary stenting in humans. Circulation 1999; 99:44.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chung IM, Gold HK, Schwartz SM, et al. Enhanced extracellular matrix accumulation in restenosis of coronary arteries after stent deployment. J Am Coll Cardiol 2002; 40:2072.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kimura T, Yokoi H, Nakagawa Y, et al. Three-year follow-up after implantation of metallic coronary-artery stents. N Engl J Med 1996; 334:561.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Asakura M, Ueda Y, Nanto S, et al. Remodeling of in-stent neointima, which became thinner and transparent over 3 years: serial angiographic and angioscopic follow-up. Circulation 1998; 97:2003.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuroda N, Kobayashi Y, Nameki M, et al. Intimal hyperplasia regression from 6 to 12 months after stenting. Am J Cardiol 2002; 89:869.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giustino G, Colombo A, Camaj A, et al. Coronary In-Stent Restenosis: JACC State-of-the-Art Review. J Am Coll Cardiol 2022; 80:348.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mehran R, Dangas G, Abizaid AS, et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation 1999; 100:1872.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoffmann R, Mintz GS. Coronary in-stent restenosis - predictors, treatment and prevention. Eur Heart J 2000; 21:1739.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kastrati A, Schömig A, Elezi S, et al. Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol 1997; 30:1428.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldberg SL, Loussararian A, De Gregorio J, et al. Predictors of diffuse and aggressive intra-stent restenosis. J Am Coll Cardiol 2001; 37:1019.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mercado N, Boersma E, Wijns W, et al. Clinical and quantitative coronary angiographic predictors of coronary restenosis: a comparative analysis from the balloon-to-stent era. J Am Coll Cardiol 2001; 38:645.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kobayashi Y, De Gregorio J, Kobayashi N, et al. Stented segment length as an independent predictor of restenosis. J Am Coll Cardiol 1999; 34:651.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lemos PA, Hoye A, Goedhart D, et al. Clinical, angiographic, and procedural predictors of angiographic restenosis after sirolimus-eluting stent implantation in complex patients: an evaluation from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) study. Circulation 2004; 109:1366.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prati F, Di Mario C, Moussa I, et al. In-stent neointimal proliferation correlates with the amount of residual plaque burden outside the stent: an intravascular ultrasound study. Circulation 1999; 99:1011.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoffmann R, Mintz GS, Mehran R, et al. Intravascular ultrasound predictors of angiographic restenosis in lesions treated with Palmaz-Schatz stents. J Am Coll Cardiol 1998; 31:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Serruys PW, Kay IP, Disco C, et al. Periprocedural quantitative coronary angiography after Palmaz-Schatz stent implantation predicts the restenosis rate at six months: results of a meta-analysis of the BElgian NEtherlands Stent study (BENESTENT) I, BENESTENT II Pilot, BENESTENT II and MUSIC trials. Multicenter Ultrasound Stent In Coronaries. J Am Coll Cardiol 1999; 34:1067.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gyöngyösi M, Yang P, Khorsand A, Glogar D. Longitudinal straightening effect of stents is an additional predictor for major adverse cardiac events. Austrian Wiktor Stent Study Group and European Paragon Stent Investigators. J Am Coll Cardiol 2000; 35:1580.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh M, Gersh BJ, McClelland RL, et al. Clinical and angiographic predictors of restenosis after percutaneous coronary intervention: insights from the Prevention of Restenosis With Tranilast and Its Outcomes (PRESTO) trial. Circulation 2004; 109:2727.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mauri L, O'Malley AJ, Cutlip DE, et al. Effects of stent length and lesion length on coronary restenosis. Am J Cardiol 2004; 93:1340.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Feyter PJ, Kay P, Disco C, Serruys PW. Reference chart derived from post-stent-implantation intravascular ultrasound predictors of 6-month expected restenosis on quantitative coronary angiography. Circulation 1999; 100:1777.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mauri L, Orav EJ, O'Malley AJ, et al. Relationship of late loss in lumen diameter to coronary restenosis in sirolimus-eluting stents. Circulation 2005; 111:321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mauri L, Orav EJ, Kuntz RE. Late loss in lumen diameter and binary restenosis for drug-eluting stent comparison. Circulation 2005; 111:3435.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mauri L, Orav EJ, Candia SC, et al. Robustness of late lumen loss in discriminating drug-eluting stents across variable observational and randomized trials. Circulation 2005; 112:2833.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ellis SG, Vandormael MG, Cowley MJ, et al. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Multivessel Angioplasty Prognosis Study Group. Circulation 1990; 82:1193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kastrati A, Schömig A, Elezi S, et al. Prognostic value of the modified american college of Cardiology/American heart association stenosis morphology classification for long-term angiographic and clinical outcome after coronary stent placement. Circulation 1999; 100:1285.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen DJ, Doucet M, Cutlip DE, et al. Impact of smoking on clinical and angiographic restenosis after percutaneous coronary intervention: another smoker's paradox? Circulation 2001; 104:773.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hasdai D, Garratt KN, Grill DE, et al. Effect of smoking status on the long-term outcome after successful percutaneous coronary revascularization. N Engl J Med 1997; 336:755.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Violaris AG, Thury A, Regar E, et al. Influence of a history of smoking on short term (six month) clinical and angiographic outcome after successful coronary angioplasty. Heart 2000; 84:299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kastrati A, Mehilli J, Dirschinger J, et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial. Circulation 2001; 103:2816.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pache J, Kastrati A, Mehilli J, et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. J Am Coll Cardiol 2003; 41:1283.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yoshitomi Y, Kojima S, Yano M, et al. Does stent design affect probability of restenosis? A randomized trial comparing Multilink stents with GFX stents. Am Heart J 2001; 142:445.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castagna MT, Mintz GS, Leiboff BO, et al. The contribution of "mechanical" problems to in-stent restenosis: An intravascular ultrasonographic analysis of 1090 consecutive in-stent restenosis lesions. Am Heart J 2001; 142:970.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kastrati A, Schömig A, Elezi S, et al. Interlesion dependence of the risk for restenosis in patients with coronary stent placement in in multiple lesions. Circulation 1998; 97:2396.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taniwaki M, Stefanini GG, Silber S, et al. 4-year clinical outcomes and predictors of repeat revascularization in patients treated with new-generation drug-eluting stents: a report from the RESOLUTE All-Comers trial (A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention). J Am Coll Cardiol 2014; 63:1617.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kastrati A, Dibra A, Mehilli J, et al. Predictive factors of restenosis after coronary implantation of sirolimus- or paclitaxel-eluting stents. Circulation 2006; 113:2293.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen MS, John JM, Chew DP, et al. Bare metal stent restenosis is not a benign clinical entity. Am Heart J 2006; 151:1260.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bossi I, Klersy C, Black AJ, et al. In-stent restenosis: long-term outcome and predictors of subsequent target lesion revascularization after repeat balloon angioplasty. J Am Coll Cardiol 2000; 35:1569.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walters DL, Harding SA, Walsh CR, et al. Acute coronary syndrome is a common clinical presentation of in-stent restenosis. Am J Cardiol 2002; 89:491.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mishkel GJ, Moore AL, Markwell S, et al. Long-term outcomes after management of restenosis or thrombosis of drug-eluting stents. J Am Coll Cardiol 2007; 49:181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fineschi M, Gori T, Pierli C, et al. Symptomatic failure after sirolimus-eluting stent implantation: a rare but challenging condition. Can J Cardiol 2007; 23:139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alfonso F, Zueco J, Cequier A, et al. A randomized comparison of repeat stenting with balloon angioplasty in patients with in-stent restenosis. J Am Coll Cardiol 2003; 42:796.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alfonso F, Augé JM, Zueco J, et al. Long-term results (three to five years) of the Restenosis Intrastent: Balloon angioplasty versus elective Stenting (RIBS) randomized study. J Am Coll Cardiol 2005; 46:756.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mehran R, Dangas G, Abizaid A, et al. Treatment of focal in-stent restenosis with balloon angioplasty alone versus stenting: Short- and long-term results. Am Heart J 2001; 141:610.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sousa JE, Costa MA, Abizaid A, et al. Sirolimus-eluting stent for the treatment of in-stent restenosis: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 2003; 107:24.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Degertekin M, Regar E, Tanabe K, et al. Sirolimus-eluting stent for treatment of complex in-stent restenosis: the first clinical experience. J Am Coll Cardiol 2003; 41:184.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tanabe K, Serruys PW, Grube E, et al. TAXUS III Trial: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation 2003; 107:559.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neumann FJ, Desmet W, Grube E, et al. Effectiveness and safety of sirolimus-eluting stents in the treatment of restenosis after coronary stent placement. Circulation 2005; 111:2107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kastrati A, Mehilli J, von Beckerath N, et al. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA 2005; 293:165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alfonso F, Pérez-Vizcayno MJ, Hernandez R, et al. A randomized comparison of sirolimus-eluting stent with balloon angioplasty in patients with in-stent restenosis: results of the Restenosis Intrastent: Balloon Angioplasty Versus Elective Sirolimus-Eluting Stenting (RIBS-II) trial. J Am Coll Cardiol 2006; 47:2152.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alfonso F, Pérez-Vizcayno MJ, Hernández R, et al. Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study. J Am Coll Cardiol 2008; 52:1621.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Habara S, Kadota K, Shimada T, et al. Late Restenosis After Paclitaxel-Coated Balloon Angioplasty Occurs in Patients With Drug-Eluting Stent Restenosis. J Am Coll Cardiol 2015; 66:14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garg S, Smith K, Torguson R, et al. Treatment of drug-eluting stent restenosis with the same versus different drug-eluting stent. Catheter Cardiovasc Interv 2007; 70:9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abe M, Kimura T, Morimoto T, et al. Sirolimus-eluting stent versus balloon angioplasty for sirolimus-eluting stent restenosis: Insights from the j-Cypher Registry. Circulation 2010; 122:42.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Byrne RA, Neumann FJ, Mehilli J, et al. Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial. Lancet 2013; 381:461.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Unverdorben M, Vallbracht C, Cremers B, et al. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis. Circulation 2009; 119:2986.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scheller B, Hehrlein C, Bocksch W, et al. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med 2006; 355:2113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stone GW, Ellis SG, O'Shaughnessy CD, et al. Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial. JAMA 2006; 295:1253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holmes DR Jr, Teirstein P, Satler L, et al. Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial. JAMA 2006; 295:1264.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ellis SG, O'Shaughnessy CD, Martin SL, et al. Two-year clinical outcomes after paclitaxel-eluting stent or brachytherapy treatment for bare metal stent restenosis: the TAXUS V ISR trial. Eur Heart J 2008; 29:1625.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siontis GC, Stefanini GG, Mavridis D, et al. Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis. Lancet 2015; 386:655.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alfonso F, Pérez-Vizcayno MJ, Cuesta J, et al. Paclitaxel-Eluting Balloons or Everolimus-Eluting Stents for In-Stent Restenosis. JACC Cardiovasc Interv 2018; 11:505.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J 2019; 40:87.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dibra A, Kastrati A, Alfonso F, et al. Effectiveness of drug-eluting stents in patients with bare-metal in-stent restenosis: meta-analysis of randomized trials. J Am Coll Cardiol 2007; 49:616.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 1587 Version 40.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32972528" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Trends and Outcomes of Restenosis After Coronary Stent Implantation in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21109112" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : In-stent restenosis in the drug-eluting stent era.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12505217" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15337693" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Beyond restenosis: five-year clinical outcomes from second-generation coronary stent trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22203694" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Very late stent thrombosis and late target lesion revascularization after sirolimus-eluting stent implantation: five-year outcome of the j-Cypher Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21646500" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Five-year clinical and angiographic outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stents: results of the Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization LATE trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32057373" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Stent-Related Adverse Events&gt;1 Year After Percutaneous Coronary Intervention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25858975" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Safety and efficacy of resolute zotarolimus-eluting stents compared with everolimus-eluting stents: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8822976" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9133506" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Histopathology of in-stent restenosis in patients with peripheral artery disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9426044" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9697822" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Neointimal tissue response at sites of coronary stenting in humans: macroscopic, histological, and immunohistochemical analyses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9884378" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Pathology of acute and chronic coronary stenting in humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12505216" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Enhanced extracellular matrix accumulation in restenosis of coronary arteries after stent deployment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8569823" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Three-year follow-up after implantation of metallic coronary-artery stents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9610528" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Remodeling of in-stent neointima, which became thinner and transparent over 3 years: serial angiographic and angioscopic follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11909579" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Intimal hyperplasia regression from 6 to 12 months after stenting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35863852" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Coronary In-Stent Restenosis: JACC State-of-the-Art Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10545431" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11052838" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Coronary in-stent restenosis - predictors, treatment and prevention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9362398" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Predictive factors of restenosis after coronary stent placement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11263602" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Predictors of diffuse and aggressive intra-stent restenosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11527611" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Clinical and quantitative coronary angiographic predictors of coronary restenosis: a comparative analysis from the balloon-to-stent era.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10483943" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Stented segment length as an independent predictor of restenosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14993127" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Clinical, angiographic, and procedural predictors of angiographic restenosis after sirolimus-eluting stent implantation in complex patients: an evaluation from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10051293" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : In-stent neointimal proliferation correlates with the amount of residual plaque burden outside the stent: an intravascular ultrasound study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9426016" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Intravascular ultrasound predictors of angiographic restenosis in lesions treated with Palmaz-Schatz stents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10520792" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Periprocedural quantitative coronary angiography after Palmaz-Schatz stent implantation predicts the restenosis rate at six months: results of a meta-analysis of the BElgian NEtherlands Stent study (BENESTENT) I, BENESTENT II Pilot, BENESTENT II and MUSIC trials. Multicenter Ultrasound Stent In Coronaries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10807464" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Longitudinal straightening effect of stents is an additional predictor for major adverse cardiac events. Austrian Wiktor Stent Study Group and European Paragon Stent Investigators.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15173022" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Clinical and angiographic predictors of restenosis after percutaneous coronary intervention: insights from the Prevention of Restenosis With Tranilast and Its Outcomes (PRESTO) trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15165911" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Effects of stent length and lesion length on coronary restenosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10534464" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Reference chart derived from post-stent-implantation intravascular ultrasound predictors of 6-month expected restenosis on quantitative coronary angiography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15655127" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Relationship of late loss in lumen diameter to coronary restenosis in sirolimus-eluting stents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15967844" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Late loss in lumen diameter and binary restenosis for drug-eluting stent comparison.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16267256" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Robustness of late lumen loss in discriminating drug-eluting stents across variable observational and randomized trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2401060" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Multivessel Angioplasty Prognosis Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10491372" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Prognostic value of the modified american college of Cardiology/American heart association stenosis morphology classification for long-term angiographic and clinical outcome after coronary stent placement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11502701" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Impact of smoking on clinical and angiographic restenosis after percutaneous coronary intervention: another smoker's paradox?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9052653" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Effect of smoking status on the long-term outcome after successful percutaneous coronary revascularization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10956296" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Influence of a history of smoking on short term (six month) clinical and angiographic outcome after successful coronary angioplasty.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11401938" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12706922" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11526357" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Does stent design affect probability of restenosis? A randomized trial comparing Multilink stents with GFX stents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11717599" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : The contribution of "mechanical" problems to in-stent restenosis: An intravascular ultrasonographic analysis of 1090 consecutive in-stent restenosis lesions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9641690" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Interlesion dependence of the risk for restenosis in patients with coronary stent placement in in multiple lesions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24530680" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : 4-year clinical outcomes and predictors of repeat revascularization in patients treated with new-generation drug-eluting stents: a report from the RESOLUTE All-Comers trial (A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16682614" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Predictive factors of restenosis after coronary implantation of sirolimus- or paclitaxel-eluting stents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16781233" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Bare metal stent restenosis is not a benign clinical entity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10807462" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : In-stent restenosis: long-term outcome and predictors of subsequent target lesion revascularization after repeat balloon angioplasty.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11867029" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Acute coronary syndrome is a common clinical presentation of in-stent restenosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17222728" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Long-term outcomes after management of restenosis or thrombosis of drug-eluting stents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17311120" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Symptomatic failure after sirolimus-eluting stent implantation: a rare but challenging condition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12957423" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : A randomized comparison of repeat stenting with balloon angioplasty in patients with in-stent restenosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16139121" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Long-term results (three to five years) of the Restenosis Intrastent: Balloon angioplasty versus elective Stenting (RIBS) randomized study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11275928" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Treatment of focal in-stent restenosis with balloon angioplasty alone versus stenting: Short- and long-term results.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12515737" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Sirolimus-eluting stent for the treatment of in-stent restenosis: a quantitative coronary angiography and three-dimensional intravascular ultrasound study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12535805" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Sirolimus-eluting stent for treatment of complex in-stent restenosis: the first clinical experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12566366" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : TAXUS III Trial: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15851617" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Effectiveness and safety of sirolimus-eluting stents in the treatment of restenosis after coronary stent placement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15644543" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16750678" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : A randomized comparison of sirolimus-eluting stent with balloon angioplasty in patients with in-stent restenosis: results of the Restenosis Intrastent: Balloon Angioplasty Versus Elective Sirolimus-Eluting Stenting (RIBS-II) trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18992651" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26139053" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Late Restenosis After Paclitaxel-Coated Balloon Angioplasty Occurs in Patients With Drug-Eluting Stent Restenosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17580367" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Treatment of drug-eluting stent restenosis with the same versus different drug-eluting stent.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20566954" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Sirolimus-eluting stent versus balloon angioplasty for sirolimus-eluting stent restenosis: Insights from the j-Cypher Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23206837" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19487593" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17101615" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16531618" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16531619" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18556716" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Two-year clinical outcomes after paclitaxel-eluting stent or brachytherapy treatment for bare metal stent restenosis: the TAXUS V ISR trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26334160" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29519385" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Paclitaxel-Eluting Balloons or Everolimus-Eluting Stents for In-Stent Restenosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30165437" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : 2018 ESC/EACTS Guidelines on myocardial revascularization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17276188" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Effectiveness of drug-eluting stents in patients with bare-metal in-stent restenosis: meta-analysis of randomized trials.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
